Efficacy and adverse reactions of osimertinib (Tagrisso)

Osimertinib is a targeted therapy drug mainly used to treat EGFR (epidermal growth factor receptor) mutation-positive advanced non-small cell lung cancer (NSCLC). The following will introduce the efficacy and adverse reactions of osimertinib in detail:

1.Efficacy:

Inhibition of tumor growth: Osimertinib, as an EGFRtyrosine kinase inhibitor, can selectively inhibit the activity of EGFR and block the conduction of the EGFR signaling pathway, thereby inhibiting the growth and proliferation of tumor cells.

Prolonged survival: Clinical trials show that osimertinib treats EGFR mutation-positive advanced NSCLC patients better than traditional chemotherapy regimens. Compared with this, it can significantly extend the progression-free survival (PFS) and overall survival (OS) of patients, and improve the survival rate of patients.

Control brain metastasis: Osimertinib has good blood-brain barrier penetration ability. In the treatment of EGFR mutation-positive NSCLC patients, it has a significant control effect on brain metastasis, and can effectively slow down or prevent the growth and spread of brain metastasis.

Improved quality of life: Osimertinib treatment regimens are generally associated with fewer adverse effects and better tolerability, so patients are generally able to maintain a better quality of life and be better able to carry out daily activities and social interactions while on treatment.

2.Adverse reactions:

Skin reaction: One of the most common adverse reactions of osimertinib is rash or dry skin, which manifests as mild rash, flushing, itching, etc. A small number of patients may develop severe rash or exfoliative dermatitis.

Gastrointestinal reactions: Osimertinib also often causes gastrointestinal reactions such as nausea, vomiting, diarrhea, and loss of appetite. These reactions are usually mild and controllable, but in some cases may affect the patient's quality of life.

Abnormal liver function: A small number of patients may develop abnormal liver function during treatment with osimertinib, manifested by symptoms such as elevated transaminases and jaundice, which require close monitoring and timely treatment.

Cardiotoxicity: Osimertinib may cause cardiotoxicity, leading to cardiovascular problems such as arrhythmias and myocardial damage. Patients require regular electrocardiogram monitoring and cardiac function assessment during treatment.

Other adverse reactions: Osimertinib may also cause fatigue, headache, visual impairment, pneumonia and other adverse reactions. These reactions are usually temporary, but in some cases treatment adjustments or supportive care may be required.

3.Manage adverse reactions:

Inform the doctor promptly: Patients should notify the doctor promptly when they discover any uncomfortable symptoms, so that the treatment plan can be adjusted in a timely manner or corresponding supportive treatment can be provided.

Maintain a good lifestyle: Maintaining good living habits, such as regular work and rest, balanced diet, moderate exercise, etc., can help reduce the occurrence and extent of some adverse reactions.

Regular monitoring: Patients should undergo regular clinical examinations and laboratory tests during treatment with osimertinib to monitor the efficacy and adverse reactions of the drug and adjust the treatment plan in a timely manner.

In summary, osimertinib, as a targeted therapy, has shown significant efficacy in the treatment of EGFR mutation-positive late-stage NSCLC patients, but it may also be accompanied by some adverse reactions. Patients should pay close attention to changes in their symptoms during treatment and communicate with their doctors in a timely manner so as to deal with adverse reactions in a timely manner and ensure the effectiveness and safety of treatment.